Premium
Enhanced antitumour immunity by combined use of temozolomide and TAT‐survivin pulsed dendritic cells in a murine glioma
Author(s) -
Kim ChangHyun,
Woo SunJe,
Park JungSun,
Kim HyeSung,
Park MiYoung,
Park SungDong,
Hong YongKil,
Kim TaiGyu
Publication year - 2007
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2007.02680.x
Subject(s) - temozolomide , survivin , immunotherapy , cd8 , adjuvant , cancer research , chemotherapy , glioma , medicine , dendritic cell , immunity , acquired immune system , antigen , immunology , immune system , cancer
Summary Although chemotherapy remains among the best treatment options for most cancers, adjuvant therapies such as dendritic cell (DC)‐based immunotherapy have been added to treatment protocols to destroy residual tumour cells. Combination treatment with low‐dose temozolomide (TMZ) chemotherapy followed by vaccination with TAT‐survivin‐pulsed DCs enhanced T‐cell responses specific for survivin and improved survival rate, as compared with DC alone or TMZ alone. Moreover, antigen‐specific immunity appears to be mediated by CD8 + T cells, as determined by in vitro T‐cell subset depletion. These studies demonstrated that a combination of low‐dose TMZ chemotherapy and TAT‐based DC immunotherapy may be a novel strategy for safe and effective treatment of malignant gliomas.